Form 4: Neurocrine Biosciences Chief Scientific Officer Executes Stock Transactions
SEC Form 4 Filing
Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, exercised stock options and sold shares under a pre-arranged trading plan.
Summary
- Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences, engaged in stock transactions on November 29, 2024.
- He acquired 4,426 shares of common stock through the vesting of restricted stock units (RSUs).
- He also sold 2,331 shares of common stock at a weighted average price of $126.286 per share.
- The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 1, 2022.
- Following these transactions, Onyia directly owns 15,449 shares of common stock.
- The RSU grant was originally made on November 29, 2021, and vests in installments.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself.
Industry Context
This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of a Rule 10b5-1 trading plan is a common practice among executives at publicly traded companies to manage their stock transactions and avoid insider trading accusations.
- The vesting schedule of the RSU is typical for executive compensation packages, often vesting over a period of several years.
- The reported share price range is consistent with the market price of Neurocrine Biosciences stock at the time of the transaction.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they represent a small portion of the total outstanding shares.
- The sale of shares by an executive could be perceived negatively by some investors, but the use of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2021-11-29 | Date of the original RSU grant to Jude Onyia. |
| 2022-09-01 | Date Jude Onyia adopted the Rule 10b5-1 trading plan. |
| 2024-02-29 | Date of purchase of 226 shares from the Employee Stock Purchase Plan. |
| 2024-11-29 | Date of stock transactions including RSU vesting and share sales. |
| 2024-12-03 | Date of signature of the Form 4 filing. |
Keywords
Neurocrine Biosciences, NBIX, stock transaction, Rule 10b5-1, insider trading, restricted stock unit, Jude Onyia, Chief Scientific Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.